Dataset from A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo

Patients receive study drug for one year (Part A). If, after the initial run-in phase, a
sustained remission is reached they will be randomly split into one of three dose groups for
another year (Part B). The maintenance of the sustained remission will be analyzed.